S. Korea to mass-produce antibody treatment of COVID-19 this month
SEOUL — South Korea plans to mass-produce an antibody treatment of the novel coronavirus later this month, health authorities said Tuesday.
The country’s drug ministry is currently reviewing phase 2/3 clinical tests for the antibody-based treatment and aims to mass-produce commercial antibodies for the novel coronavirus in September, according to Kwon Jun-wook, deputy chief at the Central Disease Control Headquarters.
Health researchers are currently analyzing results of the phase 1 trial, which was approved by the drug ministry on July 17. They also earned approval for the phase 1 study of the treatment in Britain on July 29.
For blood plasma-based treatment, health authorities said the drug ministry approved the phase 2 study of its development on Aug. 20, and six medical institutions, including Samsung Medical Center and Asan Medical Center, will verify its effectiveness and safety on COVID-19 patients.
Health authorities added the blood plasma material for the phase 2 trial will begin being produce Tuesday and supply of the substance will be completed in mid-October. (Yonhap)
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.